IBC Generium Selects Goodwin Biotechnology
News Apr 29, 2016
International Biotechnology Center “Generium”, has selected Goodwin Biotechnology, Inc. for the assay and process technology transfer, process scale‐up, and cGMP manufacturing of an IgG‐based, bispecific antibody to support early stage clinical trials.
“Our scientific staff at IBC Generium developed GNR‐047, an IgG‐based anti‐CD3 / anti‐CD19 bispecific antibody for the treatment of oncohematological diseases, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and different kinds of non‐Hodgkin’s lymphoma (NHL), and we were looking to partner with a Contact Manufacturing Organization to help us optimize the process and manufacture material to be used in Phase I clinical trials,” said Daniil Talyanskiy, Chief Business Officer at IBC Generium.
“We work with a number of companies around the world to advance our portfolio of drug candidates, and one of our primary collaborators highly recommended Goodwin Biotechnology based on the track record they had on a number of their projects that Goodwin Biotechnology had worked on over the last six years.”
“Our highly skilled scientists take great pride in working with our clients to enhance the value of their product candidates,” noted SooYoung S. Lee, PhD, Chief Operating Officer at Goodwin Biotechnology.
“We are excited to be working on IBC Generium’s cutting edge bispecific antibody, bringing to bear our multiple decades of experience in this field. And, the fact that we have been referred by one of our long‐term, satisfied clients to IBC Generium gives us immense pride; it is a validation of the technical expertise, commitment, and dedication of our staff.
Our clients appreciate our creative and flexible approach in forging partnerships with them and taking the time to listen to their challenges, then developing a customized strategy to cost effectively address their needs and deliver their product on time.”
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE